Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3Sarcoma 1

Conditions

Hodgkin Disease 45Lymphoma 22Hematologic Diseases 17Lymphoma, Large-Cell, Anaplastic 15Lymphoma, Non-Hodgkin 11Recurrence 9Lymphoma, T-Cell 8Lymphoma, T-Cell, Cutaneous 6Lymphoma, T-Cell, Peripheral 5Mycosis Fungoides 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphomatoid Papulosis 2Enteropathy-Associated T-Cell Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Melanoma 1

Interventions

Brentuximab Vedotin 3Bexarotene 2Vitamin B 12 1Salvia hispanica seed extract 1Methotrexate 1Lenalidomide 1Folic Acid 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Brentuximab Vedotin × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT01578499 2021-01-05

ALCANZA

Takeda

Phase 3 Completed
131 enrolled 24 charts
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡